All In Biotech

Drug Trial Radar · NCT01307267

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)

Last checked: Nov 19, 2026Latest source record: Mar 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

190

Actual

Start

Jun 21, 2011

Primary completion

Feb 20, 2019

Study completion Feb 20, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell
  • Carcinoma, Squamous Cell of Head and Neck
  • Malignant Melanoma

Interventions

  • PF-05082566Drug

    Intravenous, Dose escalation, once per month

  • rituximabDrug

    Intravenous, 375 mg/m2, once per week for 4 weeks

  • PF-05082566Drug

    IV, Dose escalation, once per month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion ATime frame: Cycle 1 Day 1 to Cycle 2 Day 29 in Portion A (up to 57 days, each cycle = 28 days)
  2. Number of Participants With DLTs in First 2 Cycles of Portion BTime frame: Cycle 1 Day 1 to Cycle 2 Day 29 in Portion B (up to 57 days, each cycle = 28 days)

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UC San Diego Moores Cancer Center-Investigational Drug Services

    La Jolla, California

  • UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital)

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Research Administration Office: Clinical Research Unit

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center, Drug Information Center

    Los Angeles, California

  • UCLA Bowyer Clinic

    Los Angeles, California

  • UCLA Hematology-Oncology Clinic

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • Stanford University Medical Center

    Palo Alto, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • Santa Monica UCLA Hematology & Oncology Clinic

    Santa Monica, California

  • Stanford University Medical Center

    Stanford, California

  • Georgetown University Medical Center Department of Pharmacy, Research

    Washington D.C., District of Columbia

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • The Emory Clinic, Building A

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute

    Atlanta, Georgia

  • Brigham and Woman's Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Siteman Cancer Center - St. Peters

    City of Saint Peters, Missouri

  • Siteman Cancer Center-West County

    Creve Coeur, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Washington University Infusion Center Pharmacy

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center- South County

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • The University of Texas - M.D. Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • University of Washington Medical Center

    Seattle, Washington

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Centre d'investigation clinique

    Rennes, France

  • Az. Ospedaliera-Univer. di Bologna Policlinico S. Orsola Malpighi

    Bologna, BO, Italy

  • Ospedale San Raffaele di Milano

    Milan, MI, Italy

  • Akita University Hospital

    Akita, Japan

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.